Gilead Sciences Inc. Executive Vice President-Research & Development and Chief Scientific Officer Norbert Bischofberger is moving on – though where he is going is not clear – after nearly three decades and the establishment of two multibillion-dollar franchises in HIV and hepatitis C.
Gilead's R&D Leadership Change Is End Of Bischofberger Era
Norbert Bischofberger has been with Gilead almost since its beginning and helped the company establish dominance in HIV and hepatitis C, but leaves as it's starting to build franchises in oncology and inflammation. Gilead veterans John McHutchinson and Andrew Cheng are elevated in his place.
